首页> 外文OA文献 >Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

【2h】

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

机译：II期ALK5抑制剂Galunisertib在非常低，低，中等风险的骨髓增强综合征中的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Valeria Santini; David Valcárcel; Uwe Platzbecker; Rami S. Komrokji; Ann L. Cleverly; Michael M. Lahn; Jan Janssen; Yumin Zhao; Alan Chiang; Aristoteles Giagounidis; Susan C. Guba; Ivelina Gueorguieva; Allicia C. Girvan; Mariana da Silva Ferreira; Tushar D. Bhagat; Kith Pradhan; Ulrich Steidl; Ashwin Sridharan; Britta Will; Amit Verma;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes [J] . Santini Valeria, Valcarcel David, Platzbecker Uwe, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第23期

机译：II期ALK5抑制剂Galunisertib在非常低，低，中等风险的骨髓增强综合征中的研究
2. The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions [J] . Fenaux Pierre, Platzbecker Uwe, Mufti Ghulam J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：奖牌试验：Luspatercept的3阶段，随机，双盲，安慰剂对照研究，以患有环纵向细胞（RS）非常低，低，中脑肌细胞增生综合征（MDS）的患者治疗贫血谁需要红细胞（RBC）输血
3. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. [J] . Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Journal of Clinical Oncology . 2013,第20期

机译：低度或中度风险性骨髓增生异常综合症患者中地西他滨的II期随机开放研究。
4. Azanudeoside DNA Methyltransferase Inhibitor Drugs: Update on Clinical Applications in Myelodysplastic Syndromes and Acute Myeloid Leukemia [C] . Michael Lubbert, Michael Daskalakis, Philipp N. Ser, Weissenburg Symposium Biriciana . 2016

机译：硫代稳产苷DNA甲基转移酶抑制剂药物：更新骨髓增生综合征和急性髓性白血病的临床应用
5. The Use of Prototypes to Engage Stakeholders in Low- and Middle-Income Countries During the Early Phases of Design [D] . Coulentianos, Marianna. 2020

机译：在设计的早期阶段，使用原型在低收入中的利益相关者
6. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes [O] . Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, -1

机译：低度或中度骨髓增生异常综合征患者中地西他滨的随机开放标签II期临床研究
7. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy [O] . Kantarjian, Hagop M., Giles, Francis J., Greenberg, Peter L., 2010

机译：接受阿扎胞苷治疗的中低危骨髓增生异常综合征患者罗米洛司汀2期研究
8. Studies of high-{delta} (baffled) and low-{delta} (open) pumped divertor operation on DIII-D [R] . 1998

机译：在DIII-D上研究高{delta}（挡板）和低{delta}（开放）泵送偏滤器操作

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

著录项

引文网络

相似文献

相关主题

期刊订阅